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Abstract
Pulmonary arterial hypertension (PAH) shares many hallmarks with cancer. Cancer cells acquire their hallmarks by a pathological
Darwinian evolution process built on the so-called cancer cell ‘‘identity crisis.’’ Here we demonstrate that PAH shares the most
striking features of the cancer identity crisis: the ectopic expression of normally silent tissue-specific genes.
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Introduction
Pulmonary arterial hypertension (PAH) is a pulmonary vas-
cular disease characterized by increased mean pulmonary
arterial pressure (mPAP; >25mmHg). This detrimental
rise in pulmonary blood pressure is due to distal pulmonary
artery occlusion driven by unregulated proliferation of pul-
monary arterial smooth muscle cells (PASMC) and endo-
thelial cells (PAEC) within the foci of complex vascular
lesions. During the last decade, landmark studies demon-
strated signiﬁcant parallels between PASMC/EC in cancer
and PAH,1,2 which elucidated key mechanisms of PAH
pathogenesis.1,3 Studies describing the acquisition of
cancer hallmarks by these vascular cells gave rise to the
cancer paradigm of PAH.2
These hallmarks include an increased proliferation rate,
evasion of growth suppressor, resistance to apoptosis, cellu-
lar energetic deregulation, angiogenesis in foci of complex
vascular lesions, sustained inﬂammation, genetic mutations,
and epigenetic modiﬁcations.1,2 Similar to what is observed
in cancer, epigenetic modiﬁcations have been shown to pre-
dispose and participate in PAH pathogenesis.4,5 Indeed,
germ line mutations in the bone morphogenetic protein
receptor II (BMPRII)4 and potassium channel subfamily
K member 3 (KCNK3)6 genes have been demonstrated to
participate in PAH development. Furthermore, somatic
mutations, single nucleotide polymorphisms, microsatellite
instability, and aneuploidy have also recently been found to
increase predisposition to PAH.3,7,8 For example, two sisters
with heritable PAH carry the same missense mutation in
Kru¨ppel-like factor 2 (KLF2), a gene known to participate
in nitric oxide vascular homeostasis.9 In another PAH
patient carrying a BMPRII mutation, Aldred et al.7 identi-
ﬁed a deletion in chromosome 13 resulting in the deletion of
mothers against decapentaplegic homolog 8 (Smad-8). In
both cases, these somatic mutations could participate in
cancer and PAH pathogenesis. In addition, increased
DNA damage followed by increased somatic mutation
acquisition has recently been demonstrated in PAH.10,11
Finally, there is growing evidence for genome-wide epigen-
etic modiﬁcations in PAH that lead to chromatin remodel-
ing and gene expression alterations. These modiﬁcations
include varied expression of epigenetic modiﬁers and readers
including histone deacetylases (HDACs)12 and BRD4,13
DNA methylation modiﬁcations,14,15 and microRNAs.16
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In cancer, genetic mutations and epigenetic modiﬁcations
pave the way for the so-called cancer cell ‘‘identity crisis,’’
characterized by abnormal repression of cell-type-speciﬁc
genes (from the diﬀerentiated phenotype) concomitant
with the aberrant activation of ‘‘oﬀ-context’’ genes (nor-
mally expressed in other cell types or during diﬀerent devel-
opmental stage) (Fig. 1a).17 These modiﬁcations in gene
expression lead to a loss of the cells’ identity (i.e. phenotype)
and the development of a full identity crisis (aberrant cell
commitment). In cancer, the most striking example of this
identity crisis is the activation of normally silent tissue-
speciﬁc genes, such as male germline or placenta-speciﬁc
genes.17 One hypothesis is that the development of this iden-
tity crisis provides a fertile ground for initiating a patho-
logical Darwinian evolution process,18 leading to the
acquisition of cancer hallmarks (Fig. 1a). In this view,
after the ﬁrst pro-cancerous event such as genetic and/or
epigenetic modiﬁcation, most altered cells would die from
lethal genomic abnormalities. A few of them, however,
would survive after accumulating speciﬁc ‘‘advantageous’’
genetic and epigenetic modiﬁcations leading to clonal
expansion and growth. In cancer, this mechanism is sup-
ported by the monoclonal nature of cancer cells; whereas
in idiopathic PAH (IPAH), clonal PAEC growth may take
place within the plexiform lesions.19 Since PAH shares
numerous hallmarks with cancer, we hypothesized that
PAH could be characterized by a similar identity crisis
and activation of normally silent tissue-speciﬁc genes. In
order to investigate our hypothesis in the most elegant and
irrefutable way, we aimed to identify aberrant activation of
normally silent genes by employing a microarray analysis-
based strategy that we recently developed.17
Methods
Patient population
In this study, we analyzed the lungs of one male and one
female with IPAH and one female with PAH associated with
systemic scleroderma (mean age¼ 47 years, mPAP¼
49.5mmHg) and compared them to three non-PAH female
lungs (mean age¼ 64 years). Individuals previously gave
signed informed consent in accordance with Laval
University and the IUCPQ Biosafety and Ethics
Committee (CER20773).
Microarray analysis
The detection of genes ectopically expressed from the tran-
scriptomic analysis was carried out with a similar strategy as
described by Rousseau et al.17 Brieﬂy, using publicly avail-
able transcriptomic data from normal human tissue, a list of
506 genes with an expression restricted to the germline or
the placenta tissue was deﬁned. An extended list of genes
was obtained by adding genes with a predominant expres-
sion in the germline, embryonic stem (ES) cells, or in the
placenta on the basis of their mean expression level in one
of these tissues being above a threshold deﬁned as the
mean expression in a series of 112 adult non-germline
tissuesþ 3*standard deviations.17 The aberrant expres-
sions of the abovementioned genes were systematically
detected using the transcriptomic data of the samples from
patients with PAH and a threshold value corresponding to
the mean value in the three control samplesþ 3*standard
deviations.
Meta-analysis
In order to conﬁrm the expression of genes found to be
ectopically expressed in our microarray analysis, we investi-
gated their expression by meta-analysis using the public
Illumina microarray repository database, Nextbio.20
Nextbio allows user-friendly access to microarray data
using a consistent analysis pipeline between datasets as
described by Kupershmidt et al.20 We found three relevant
microarray datasets in this microarray repository database;
namely, GSE53408 comparing the lung gene expression of
11 controls to 12 patients with severe PAH, GSE21284 com-
paring primary cultured PASMC from two control to two
PAH patients, and GSE15197 comparing the lung gene
expression of 13 control to 18 PAH patients and eight
patients with pulmonary hypertension associated with pul-
monary ﬁbrosis.
Results
Our analysis revealed an aberrant expression of 40 genes in
all three human PAH lungs (Fig. 1b). Among them, four
genes (C15ofr32, PSG11, C15orf43, and KRTAP21-1) have
normal expression strictly restricted to testis or placenta
(Fig. 1b, Group 1), another four (CECR2, TTLL4,
MRPS25, QSER1) have predominant expression in ES
cells (Fig. 1b, Group 3), and the remaining 32 genes have
predominant expression in germline cells (Fig. 1b, Group 2).
Furthermore, considering only the genes whose expression is
normally restricted to male germline or placenta, we
observed the ectopic activation of 47 of these genes in at
least one PAH patient (Fig. 1c).
These results were further conﬁrmed by meta-analysis
using Nextbio. Indeed, bio-informatics research in the
Nextbio database revealed that, despite using a diﬀerent
microarray platform (Illumina vs. Aﬀymetrix array), diﬀer-
ent approaches and diﬀerent populations, three previous
microarray studies also documented that 18 of the genes
identiﬁed above have aberrant expression in PAH (Fig. 1d
and 1e). Among these 18 genes, 13 of them were found to
have altered expression in all three PAH patients (Fig. 1d)
and ﬁve genes among the 40 genes with restricted tissues-
speciﬁc expression (Fig. 1e). Presently, most of the genes
we identiﬁed have no known function, highlighting the
probable absence of a functional role in PAH
pathogenesis.
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Fig. 1. (a) Proposed model of identity crisis leading to PAH pathogenesis by a Darwinian evolution process. Genetic mutation and epigenetic
rearrangement lead to aberrant gene expression and identity crisis development. In turn, identity crisis by a Darwinian evolution process gives
rise to cancer cells hallmark acquisition and tumor development. In PAH, the same evolutionary process, with different selective pressure, would
lead to PAH cancer hallmark acquisition, pulmonary arteries obstruction, and complex intimal lesions. (b) Ectopic expression of highly specific
germline, placental, and embryonic genes in PAH lung. Ectopic expression heat map showing the ectopic expression in all human PAH lungs of
highly specific germline, placental, and embryonic stem cell genes and their lack of expression in control lungs. Heat map has been divided into
three groups: (1) placental and testis restricted expression; (2) germline cells predominant expression; (3) embryonic stem cells predominant
expression (c) neo-expression of testis and placental restricted genes in PAH lung. Heat map illustrating the neo-expression in human PAH lungs
of testis and placenta restricted genes and their absence of expression in control lungs. (d, e) Highly specific and restricted genes expression in
previously performed microarray. (d) Aberrant expression of the same highly specific germline, placental and embryonic stem cell genes and
(e) the neo-expression in human PAH lungs of testis and placenta restricted genes from microarray expression data of experiments previously
performed in human PAH.17 These microarray expression analyses were performed on 12 lungs from end-stage PAH vs. 11 control patients (GSE
53408) (black); two primary isolated smooth muscle cells of PAH patients vs. two primary isolated control smooth muscle cells (GSE 21284)
(gray); lungs from eight PAH patients associated with pulmonary fibrosis vs. 13 controls (GSE 15197) (yellow); lung from 18 PAH patients vs. 13
controls (GSE 15197) (green).
Pulmonary Circulation Volume 8 Number 3 | 3
Discussion
To our knowledge, this is the ﬁrst study demonstrating the
aberrant activation of normally silent tissue-speciﬁc genes in
the lungs of human PAH patients. Indeed, 23 of the altered
genes have already been demonstrated in PAH, but this is
the ﬁrst time that a systematic investigation of oﬀ-context
gene expression has been done in the context of PAH. This
demonstration of an ectopic gene expression in PAH gives
the ﬁrst strong evidence of a cancer-like identity crisis in
PAH. This also reinforces the potential role of epigenetic
landscape modiﬁcation in PAH pathogenesis12–14,16 as a
mechanism to provide fertile ground for a pathological
Darwinian evolution process.
Interestingly, while all the PAH patients we tested
showed ectopic gene expression, they did not re-express
the same set of genes. In our view, this diﬀerential re-expres-
sion is due to stochastic gene expression modiﬁcation driven
by the Darwinian evolution process. Thus, in this view, it is
not the re-expression of a deﬁned set of oﬀ-context genes
which is of interest but rather the process of re-expression
itself which reﬂects the underlying pathological mechanism
that gives rise to the identity crisis. Nonetheless, a potential
role for some of these ectopically expressed genes cannot be
excluded, particularly for the genes we found expressed in all
of our patients including embryonic stem cell genes which
could participate in recruitment of progenitor cells known to
play a role in PAH pathogenesis.21
Other studies are needed to investigate the speciﬁc role of
these genes in a larger cohort of PAH patients. Indeed, the
number of patients used in our study as well as their hetero-
geneity (e.g. sex, age, medication, and associated diseases)
could lead to the generation of false-positive and false-nega-
tive results. Nonetheless, the generation of false-positive
results is unlikely, considering the nature of genes investi-
gated in the present study are epigenetically tightly locked in
somatic cells.17 The generation of false-negative results
cannot be controlled in our study setting; however, if this
bias occurs, it will not nullify our ﬁnding of an identity crisis
in PAH as false-negative results may only aﬀect the number
of genes found but not the demonstration of an oﬀ-context
gene expression in PAH.
Taken together, our results demonstrate an oﬀ-context
expression of normally silent genes which supports our
hypothesis that an identity crisis is occurring in PAH.
Much like in cancer, this oﬀ-context gene expression could
pave the way for potential new predictive markers in PAH.
In cancer, the ectopic expression of cancer testis antigens
(CTAs), a class of immunogenic proteins with a testis- and
tumor-restricted pattern of expression, are already use as
predictive markers.22
In conclusion, our study brings the ﬁrst evidence of an
identity crisis occurring in the lungs of PAH patients by
demonstrating the aberrant and oﬀ-context expression of
normally silent, tissue-speciﬁc genes. In our view, this ecto-
pic gene expression is due to a pathological Darwinian evo-
lution process evolving on the fertile ground of genome-wide
epigenetic modiﬁcations already suggested in PAH.12–16
This observation of an identity crisis in PAH strengthens
the parallels that can be established between the PAH con-
dition and cancer where a similar ﬁnding has been reported.
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